X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AR-501 is a novel inhaled formulation of gallium citrate with broad-spectrum anti-infective activity involving iron acquisition and metabolism, is being developed to treat chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
AR-501 is a novel inhaled formulation of gallium citrate with broad-spectrum anti-infective activity involving iron acquisition and metabolism, is being developed to treat chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
AR-501 is a novel, small molecule and an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $12.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 12, 2022
Details:
AR-501 (gallium citrate) is an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
FDA also concurred with the Company's proposal to expand the originally planned Phase 2a protocol design into a Phase 2a/2b study of Company's AR-501 for the treatment of chronic lung infections associated with cystic fibrosis (CF).
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
AR-501 is being developed as a once-per-week dosing regimen that is self-administered using a hand-held nebulizer device. Phase 1 portion of the Phase 1/2a trial, 48 healthy volunteers were treated with either single or multiple weekly dose regimens with no adverse effects.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
